STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.
STAT
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from STAT.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
STAT (www.statnews.com), a Tier B publisher, filed this report on . CurrentWire published this page 1 minute later, on .
Signal breakdown
CurrentWire ranked this story 67.2 of 100 in the snapshot this page was rendered from.
- Freshness
- 29.2 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 10 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (none), Scholar Rock (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.